NASDAQ:NAOV

NanoVibronix Stock Forecast, Price & News

$0.85

+0.00 (+0.54 %)

(As of 04/16/2021 10:15 AM ET)

Add

Compare

Today's Range

$0.79

Now: $0.85▼

$0.86

50-Day Range

$0.90

MA: $1.07▼

$1.22

52-Week Range

$0.54

Now: $0.85▼

$3.50

Volume1,811 shs

Average Volume3.85 million shs

Market Capitalization$11.45 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.07

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:NAOV

Previous Symbol

CUSIPN/A

CIK1326706

Webwww.nanovibronix.com

Phone914-233-3004

Employees10

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.01

Current Ratio10.73

Quick Ratio10.43

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$530,000.00

Price / Sales21.60

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.30 per share

Price / Book2.85

Profitability

EPS (Most Recent Fiscal Year)($0.83)

Net Income$-5,790,000.00

Net Margins-727.90%

Return on Equity-418.55%

Return on Assets-218.34%

Miscellaneous

Outstanding Shares13,394,000

Market Cap$11.45 million

Next Earnings Date7/5/2021 (Estimated)

OptionableNot Optionable

Headlines

Form DEFA14A NanoVibronix, Inc. - StreetInsider.com
April 14, 2021 | streetinsider.com

NanoVibronix Adjourns Special Meeting of Stockholders Nasdaq:NAOV - GlobeNewswire
April 14, 2021 | globenewswire.com

25 Stocks Moving in Monday's Pre-Market Session – Benzinga - Benzinga
April 6, 2021 | benzinga.com

Chembio Diagnostics, Nano-X Imaging leads healthcare gainers; Molecular Templates, ACADIA Pharmaceuticals among major losers - Seeking Alpha
April 5, 2021 | seekingalpha.com

NanoVibronix Adjourns Special Meeting of Stockholders - Business Wire
April 1, 2021 | businesswire.com

NanoVibronix Adjourns Special Meeting of Stockholders
March 31, 2021 | finance.yahoo.com

NanoVibronix, Inc. (NASDAQ:NAOV) Sees Large Growth in Short Interest
March 30, 2021 | americanbankingnews.com

MARA, BLUE, TME and CAN among premarket gainers - Seeking Alpha
March 29, 2021 | seekingalpha.com

Dollar General, ZTO Express leads the premarket losers' pack - Seeking Alpha
March 18, 2021 | seekingalpha.com

NanoVibronix UroShield Joins PainShield on Federal Supply Schedule, Expanding Access to VA Market - Business Wire
March 2, 2021 | businesswire.com

NanoVibronix UroShield Joins PainShield on Federal Supply Schedule, Expanding Access to VA Market
March 2, 2021 | finance.yahoo.com

NanoVibronix Reports Schedule Published by NICE for Review of UroShield® Device - Business Wire
February 11, 2021 | businesswire.com

NanoVibronix (NAOV) Regains Nasdaq Compliance - StreetInsider.com
February 3, 2021 | streetinsider.com

Why Is It Moving? Looking Into Why NanoVibronix's Stock is Trading Higher Today - Benzinga
February 3, 2021 | benzinga.com

NanoVibronix Regains Nasdaq Compliance - Business Wire
February 3, 2021 | businesswire.com

NanoVibronix Regains Nasdaq Compliance
February 3, 2021 | finance.yahoo.com

NAOV Stock: 7 Things to Know About Medical Device Company NanoVibronix - InvestorPlace
January 24, 2021 | investorplace.com

NAOV Stock: 7 Things to Know About Medical Device Company NanoVibronix - Nasdaq
January 24, 2021 | nasdaq.com

38 Stocks Moving in Friday's Pre-Market Session Benzinga - Benzinga
January 22, 2021 | benzinga.com

NanoVibronix Issues Letter to Shareholders
January 19, 2021 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.53 out of 5 stars

Medical Sector

1503rd out of 2,021 stocks

Surgical Appliances & Supplies Industry

34th out of 40 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for NanoVibronix.

2.0 Community Rank

Outperform Votes
NanoVibronix has received 71 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
NanoVibronix has received 107 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
NanoVibronix has received 60.11% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about NanoVibronix and other stocks. Vote “Outperform” if you believe NAOV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NAOV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
NanoVibronix does not currently pay a dividend.
Dividend Growth
NanoVibronix does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NanoVibronix insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 19.80% of the stock of NanoVibronix is held by insiders.
Percentage Held by Institutions
Only 7.31% of the stock of NanoVibronix is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for NanoVibronix are expected to grow in the coming year, from ($0.81) to ($0.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NanoVibronix is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NanoVibronix is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NanoVibronix has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$0.85

+0.00 (+0.54 %)

(As of 04/16/2021 10:15 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive NAOV News and Ratings via Email

Sign-up to receive the latest news and ratings for NAOV and its competitors with MarketBeat's FREE daily newsletter.

NanoVibronix (NASDAQ:NAOV) Frequently Asked Questions

What stocks does MarketBeat like better than NanoVibronix?

Wall Street analysts have given NanoVibronix a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but NanoVibronix wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NanoVibronix?

NanoVibronix saw a decrease in short interest in March. As of March 31st, there was short interest totaling 161,300 shares, a decrease of 34.6% from the March 15th total of 246,700 shares. Based on an average daily volume of 4,080,000 shares, the days-to-cover ratio is currently 0.0 days.
View NanoVibronix's Short Interest.

When is NanoVibronix's next earnings date?

NanoVibronix is scheduled to release its next quarterly earnings announcement on Monday, July 5th 2021.
View our earnings forecast for NanoVibronix.

How were NanoVibronix's earnings last quarter?

NanoVibronix, Inc. (NASDAQ:NAOV) announced its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.21) earnings per share for the quarter. The company earned $0.05 million during the quarter. NanoVibronix had a negative net margin of 727.90% and a negative trailing twelve-month return on equity of 418.55%.
View NanoVibronix's earnings history.

How has NanoVibronix's stock price been impacted by COVID-19?

NanoVibronix's stock was trading at $2.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NAOV stock has decreased by 68.9% and is now trading at $0.8547.
View which stocks have been most impacted by COVID-19.

Who are NanoVibronix's key executives?

NanoVibronix's management team includes the following people:

Mr. Brian M. Murphy, CEO & Director (Age 64, Pay $288.23k)
Mr. Stephen R. Brown CPA, CPA, CFO & Accounting Officer (Age 65, Pay $180k)
Mr. Amir Rippel, VP of Marketing
Mrs. Lindsey Harrison, VP of Sales
Dr. Harold Jacob, Chief Medical Officer & Director (Age 67)

Who are some of NanoVibronix's key competitors?

Some companies that are related to NanoVibronix include Allied Healthcare Products (AHPI), Bionik Laboratories (BNKL), Advanced Biomedical Technologies (ABMT), Avitar (AVTI), Pathfinder Cell Therapy (PFND) and PC Group (PCGR).
View all of NAOV's competitors.

What other stocks do shareholders of NanoVibronix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoVibronix investors own include T2 Biosystems (TTOO), ADMA Biologics (ADMA), (CGC), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO), Tonix Pharmaceuticals (TNXP), BIO-key International (BKYI), Digital Ally (DGLY), iBio (IBIO) and Inpixon (INPX).

What is NanoVibronix's stock symbol?

NanoVibronix trades on the NASDAQ under the ticker symbol "NAOV."

How do I buy shares of NanoVibronix?

Shares of NAOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NanoVibronix's stock price today?

One share of NAOV stock can currently be purchased for approximately $0.85.

How much money does NanoVibronix make?

NanoVibronix has a market capitalization of $11.45 million and generates $530,000.00 in revenue each year. The company earns $-5,790,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does NanoVibronix have?

NanoVibronix employs 10 workers across the globe.

What is NanoVibronix's official website?

The official website for NanoVibronix is www.nanovibronix.com.

Where are NanoVibronix's headquarters?

NanoVibronix is headquartered at 525 Executive Blvd, Elmsford NY, 10523.

How can I contact NanoVibronix?

NanoVibronix's mailing address is 525 Executive Blvd, Elmsford NY, 10523. The company can be reached via phone at 914-233-3004 or via email at [email protected]

This page was last updated on 4/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here